These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1407000)

  • 41. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
    Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
    Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ; Verheijen JH
    Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant tissue-type plasminogen activator ameliorates ischemic derangements induced by thrombotic occlusion in closed chest anesthetized dogs.
    Egashira K; Kawai K; Nagano M; Sakuma A; Nakamura M; Tomoike H
    J Am Coll Cardiol; 1992 Jul; 20(1):218-25. PubMed ID: 1607528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys.
    Oikawa K; Kamimura H; Watanabe T; Miyamoto I; Higuchi S
    Thromb Res; 2001 Mar; 101(6):493-500. PubMed ID: 11323007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
    Martin U; Sponer G; Strein K
    Blood Coagul Fibrinolysis; 1993 Apr; 4(2):235-42. PubMed ID: 8388740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits.
    Agnelli G; Buchanan MR; Fernandez F; Hirsh J
    Thromb Res; 1985 Dec; 40(6):769-77. PubMed ID: 3937287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
    Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
    J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats.
    Martin U; Doerge L; Stegmeier K; Müller-Beckmann B
    Drug Metab Dispos; 1996 Mar; 24(3):288-92. PubMed ID: 8820418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U; Sponer G; König R; Smolarz A; Meyer-Sabellek W; Strein K
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis.
    Martin U; Kohnert U; Stern A; Popp F; Fischer S
    Thromb Haemost; 1996 Dec; 76(6):1096-101. PubMed ID: 8972037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
    Lu HR; Gold HK; Wu Z; Yasuda T; Pauwels P; Rapold HJ; Napier M; Bunting S; Collen D
    Thromb Haemost; 1992 Jun; 67(6):686-91. PubMed ID: 1509410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.